Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for: 1. Teriflunomide Tablets, 7 mg and 14 mg 2. Tobramycin Ophthalmic Solution USP, 0.3% Please find enclosed herewith our press releases for both the products separately. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s). Alembic Pharmaceuticals Ltd - 533573 - Shareholding for the Period Ended March 31, 2019
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliance Certificate For The Half Year Ended 31St March, 2019.
With reference to the captioned subject, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent viz. Link Intime India Private Limited, which is a SEBI approved Category-I Registrar & Transfer Agent, registered with the Securities and Exchange Board of India (SEBI Registration Number : INR000004058). We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2019
With reference to the captioned subject, we enclose herewith Certificate under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 31st March, 2019, issued by M/s. Samdani Shah & Kabra, Practising Company Secretaries, Vadodara. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
With reference to the captioned subject, this is to inform the exchange that there was an error in the second paragraph of the press release submitted with the stock exchanges. The second paragraph of the press release be read as 'Bimatoprost Ophthalmic Solution, 0.03% have an estimated market size of US$ 10 million for twelve months ending December 2018 according to IQVIA.' Please find enclosed herewith our revised press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Bimatoprost Ophthalmic Solution, 0.03%. Please find enclosed herewith our press release. We request you to kindly take the same on record. Company news: Alembic Pharmaceuticals
Alembic Pharmaceuticals on Friday said that it has received Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) f ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its Formulation Facility At Panelav
This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food & Drug Administration (USFDA) for the inspection carried out by them at our Formulation Facility at Panelav during the period from 22nd October, 2018 to 26th October, 2018. We request you to kindly take the same on record.